Table 2.
Comparison of parameters of patients with RA with and without neuropathy
| Parameter | Patients with neuropathy (n=67) | Patients without neuropathy (n=22) | P |
|---|---|---|---|
| Age (years) | 54.34±11.644 | 36.32±13.56 | 0.005 |
| Morning stiffness | 31.19±17.94 | 75.09±19.51 | 0.179 |
| Disease duration (years) | 15.07±7.29 | 5.32±5.51 | 0.000 |
| DAS-28 score | 6.32±0.544 | 4.79±0.83 | 0.000 |
| RF positivity | 89.39±54.24 | 10.711±1.78 | 0.35 |
| Hemoglobin | 10.71±1.78 | 12.861±0.98 | 0.000 |
| ESR | 75.16±18.33 | 50.54±2.50 | 0.000 |
| Absence of tendon reflexes | 27 (40.29%) | 2 (9.09%) | 0.001 |
| Loss of knee jerk | 3 (4.47%) | 0 | 0.001 |
| Erosions on X-ray | 50 (74.62%) | 8 (36.36%) | 0.001 |
| Superficial fine touch sensory loss | 14 (20.89%) | 0 | 0.001 |
| Temperature loss | 10 (14.92%) | 0 | 0.001 |
| Loss of joint position and vibration sense | 3 (4.1%) | 0 | 0.000 |
| Motor abnormalities | 6 (8.95%) | 0 | 0.000 |
| NSAIDS | 67 (100%) | 20 (90.09%) | 0.13 |
| Methotrexate | 63 (94.02%) | 7 (31.81%) | 0.000 |
| Hydroychloroquine | 54 (80.59%) | 4 (18.18%) | 0.000 |
| Sulfasalazine | 47 (70.14%) | 4 (18.18%) | 0.000 |
| Leflunomide | 26 (38.80%) | 0 | 0.000 |
| ILD | 10 (14.9%) | 7 (31.81%) | 0.1 |
| Subcutaneous nodules | 7 (10.4%) | 6 (27.2%) | 0.006 |
| Muscle wasting (upper limb) | 16 (23.8%) | 1 (4.5%) | 0.01 |
| Muscle wasting (lower limb) | 12 (17.9%) | 1 (4.5%) | 0.02 |
| Anti-CCP antibody positive | 44 (65.6%) | 5 (22.7%) | 0.000 |
| Tinel’s sign | 22 (32.8%) | 2 (9%) | 0.01 |
| Phalen’s sign | 7 (10.4%) | 1 (4.5%) | 0.045 |
| HAQ-D1 (mean±SD) | 0.63±0.24 | 0.21±0.3 | 0.02 |
| Pain sensitivity (VAS: 0-100) | 86.2±13.6 | 45.3±22.6 | 0.03 |
RA: Rheumatoid arthritis; DAS: Disease activity score; RF: Rheumatoid factor; ESR: Erythrocyte sedimentation rate; ILD: Interstitial lung disease; HAQ-D1: Health Assessment Questionnaire Disability Index; SD: Standard deviation; VAS: Visual analog scale